Trial Profile
Efficacy of silodosin plus fesoterodine versus silodosin plus mirabegron in patients with benign prostatic enlargement complicated by overactive bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2021
Price :
$35
*
At a glance
- Drugs Silodosin (Primary) ; Fesoterodine; Mirabegron
- Indications Overactive bladder
- Focus Therapeutic Use
- 07 Jun 2017 New trial record
- 16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association